• 1
    Taylor AT, Stafford MA, Jones OW. Properties of thymidine kinase partially purified from human fetal and adult tissue. J Biol Chem 1972;247: 193035.
  • 2
    Harvey D, Bradshaw HD. Molecular cloning and cell cycle-specific regulation of a functional human thymidine kinase gene. Proc Natl Acad Sci USA 1983;80: 558891.
  • 3
    Johansson M, Karlsson A. Cloning of the cDNA and chromosome localization of the gene for human thymidine kinase 2. J Biol Chem 1997;272: 84548.
  • 4
    Berenstein D, Christensen JF, Kristensen T, Hofbauer R, Munch-Petersen B. 2000. Valine, not methionine, is amino acid 106 in human cytosolic thymidine kinase (TK1). J Biol Chem 2000;275: 3218792.
  • 5
    Adler R, McAuslan BR. Expression of thymidine kinase variants is a function of the replicative state of cells. Cell 1974;2: 1137.
  • 6
    Ellims PH, Van der Weyden MB, Medley G. Thymidine kinase isoenzymes in human malignant lymphoma. Cancer Res 1981;41: 6915.
  • 7
    O'Neill KL, Hoper M, Odling-Smee GW. Can thymidine kinase levels in breast tumors predict disease recurrence? J Natl Cancer Inst 1992;84: 18258.
  • 8
    Hallek M, Wanders L, Strohmeyer S, Emmerich B. Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications. Ann Hematol 1992;65: 15.
  • 9
    Hallek M, Touitou Y, Levi F, Mechkouri M, Bogdan A, Bailleul F, Senekowitsch R, Emmerich B. Serum thymidine kinase levels are elevated and exhibit diurnal variations in patients with advanced ovarian cancer. Clin Chim Acta 1997;267: 15566.
  • 10
    Robertson JF, O'Neill KL, Thomas MW, McKenna PG, Blamey RW. Thymidine kinase in breast cancer. Br J Cancer 1990;62: 6637.
  • 11
    Romain S, Bendahl PO, Guirou O, Malmstrom P, Martin PM, Fern M. DNA-synthesizing enzymes in breast cancer (thymidine kinase, thymidylate synthase and thymidylate kinase): association with flow cytometric S-phase fraction and relative prognostic importance in node-negative premenopausal patients. Int J Cancer 2001;95: 5661.
  • 12
    Gronowitz JS, Steinholtz L, Kallander CF, Hagberg H, Bergh J. Serum deoxythymidine kinase in small cell carcinoma of the lung. Relation to clinical features, prognosis and other biochemical markers. Cancer 1986;58: 1118.
  • 13
    Lewenhaupt A, Ekman P, Eneroth P, Nilsson B. Tumour markers as prognostic aids in prostatic carcinoma. Br J Urol 1990;66: 1827.
  • 14
    Fujiwaki R, Hata K, Moriyama M, Iwanari O, Katabuchi H, Okamura H, Miyazaki K. Clinical value of thymidine kinase in patients with cervical carcinoma. Oncology 2001;61: 4754.
  • 15
    Danenberg PV. Thymidylate synthetase—a target enzyme in cancer chemotherapy. Biochem Biophys Acta 1977;473: 7392.
  • 16
    Navalgund LG, Rossana C, Muench AJ, Johnson LF. Cell cycle regulation of thymidylate synthetase gene expression in cultured mouse fibroblasts. J Biol Chem 1980;255: 738690.
  • 17
    Iltzsch MH, el Kouni MH, Cha S. Kinetic studies of thymidine phosphorylase from mouse liver. Biochemistry 1985;24: 6799807.
  • 18
    Kitazono M, Takebayashi Y, Ishitsuka K, Takao S, Tani A, Furukawa T, Miyadera K, Yamada Y, Aikou T, Akiyama S. Prevention of hypoxia-induced apoptosis by the angiogenic factor thymidine phosphorylase. Biochem Biophys Res Commun 1998;253: 797803.
  • 19
    Moghaddam A, Zhang HT, Fan TP, Hu DE, Lees VC, Turley H, Fox SB, Gatter KC, Harris AL, Bicknell R. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad USA 1995;92: 9981002.
  • 20
    Canellakis ES. Pyrimidine metabolism—enzymatic pathways of uracil and thymidine degradation. J Biol Chem 1956;221: 31522.
  • 21
    Tuchman M, O'Dea RF, Ramnaraine ML, Mirkin BL. Pyrimidine base degradation in cultured murine C-1300 neuroblastoma cells and in situ tumors. J Clin Invest 1988;81: 42530.
  • 22
    Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 1998;58: 68590.
  • 23
    Fujiwaki R, Hata K, Nakayama K, Fukumoto M, Miyazaki K. Gene expression for dihydropyrimidine dehydrogenase and thymidine phosphorylase influences outcome in epithelial ovarian cancer. J Clin Oncol 2000;18: 394651.
  • 24
    Fujiwaki R, Hata K, Nakayama K, Fukumoto M, Miyazaki K. Thymidylate synthase expression in epithelial ovarian cancer: relationship with thymidine phosphorylase expression and prognosis. Oncology 2000;68: 24752.
  • 25
    International Federation of Gynecology and Obstetrics. Changes in definitions of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol 1989;156: 2634.
  • 26
    Hata K, Kamikawa T, Arao S, Tashiro H, Katabuchi H, Okamura H, Fujiwaki R, Miyazaki K, Fukumoto M. Expression of the thymidine phosphorylase gene in epithelial ovarian cancer. Br J Cancer 1999;79: 184854.
  • 27
    Serov SF, Scully RE, Sobin LH. International histological classification of tumors, 9. Histological typing of ovarian tumors. Geneva: WHO, 1973.
  • 28
    Romain S, Martin PM, Klijn JG, van Putten WL, Look MP, Guirou O, Foekens JA. DNA-synthesis enzyme activity: a biological tool useful for predicting anti-metabolic drug sensitivity in breast cancer? Int J Cancer 1997;74: 15661.
  • 29
    Gronowitz JS, Kallander FR, Diderholm H, Hagberg H, Pettersson U. Application of an in vitro assay for serum thymidine kinase: results on viral disease and malignancies in humans. Int J Cancer 1984;33: 512.
  • 30
    Lowry OH, Rosebrough NJ, Farr AL, Rano RI. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193: 26575.
  • 31
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53: 45781.
  • 32
    Brown NS, Jones A, Fujiyama C, Harris AL, Bicknell R. Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors. Cancer Res 2000;60: 6298302.
  • 33
    Griffiths L, Dachs GU, Bicknell R, Harris AL, Stratford IJ. The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo. Cancer Res 1997;57: 5702.
  • 34
    Jiang W, Lu Z, He Y, Diasio RB. Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil–based chemotherapy. Clin Cancer Res 1997;3: 3959.
  • 35
    McLeod HL, Sludden J, Murray GI, Keenan RA, Davidson AI, Park K, Koruth M, Cassidy J. Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours. Br J Cancer 1998;77: 4615.
  • 36
    Look KY, Moore DH, Sutton GP, Prajda N, Abonyi M, Weber G. Increased thymidine kinase and thymidylate synthase activities in human epithelial ovarian carcinoma. Anticancer Res 1997;17: 23536.
  • 37
    Barnabei VM, Miller DS, Bauer KD, Murad TM, Rademaker AW, Lurain JR. Flow cytometric evaluation of epithelial ovarian cancer. Am J Obstet Gynecol 1989;162: 158490.
  • 38
    Scanlon KJ, Kashani-Sabet M, Sowers LC. Overexpression of DNA replication and repair enzymes in cisplatin-resistant human colon carcinoma HCT8 cells and circumvention by azidothymidine. Cancer Commun 1989;1: 26975.
  • 39
    Ju J, Pedersen-Lane J, Maley F, Chu E. Regulation of p53 expression by thymidylate synthase. Proc Natl Acad Sci USA 1999;96: 376974.
  • 40
    Hata K, Fujiwaki R, Nakayama K, Fukumoto M, Miyazaki K. Expression of TP and TIE2 genes in normal ovary with corpus luteum and in ovarian cancer: correlation with ultrasound-derived peak systolic velocity. Mol Hum Reprod 2000;6: 31923.
  • 41
    Hata K, Fujiwaki R, Maede Y, Nakayama K, Fukumoto M, Miyazaki K. Expression of thymidine phosphorylase in epithelial ovarian cancer: correlation with angiogenesis, apoptosis and ultrasound-derived peak systolic velocity. Gynecol Oncol 2000;77: 2634.
  • 42
    Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996;6: 98694.
  • 43
    Coleman RL, Miller DS. Topotecan in the treatment of gynecologic cancer. Semin Oncol 1997;24: 5563.
  • 44
    Voeller DM, Grem JL, Pommier Y, Paull K, Allegra CJ. Identification and proposed mechanism of action of thymidine kinase inhibition associated with cellular exposure to camptothecin analogs. Cancer Chemother Pharmacol 2000;45: 40916.